$XBIT Income Statement | Understand Stock

$XBIT

$1.85 -$0.08 (4.15%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Manufacturing Revenue
Clinical Trial Service Revenue
Product and Service, Other
Total revenue

Cost of goods sold
Manufacturing Revenue
Clinical Trial Service Revenue
Total cost of goods sold

Gross margin
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest income
Gain from Janssen Transaction
Interest expense
Other expense
Foreign exchange gain (loss)
Total other income
Income before income taxes
Income tax (expense) benefit
Net loss
Net loss per share—basic and diluted (in dollars per share)
Shares used to compute basic and diluted net loss per share (in shares)

Comments